Emphasis of neutrophil to lymphocyte for prediction of Gleason groups in patient who underwent prostate biopsy

Year 2018, Volume: 13 Issue: 2, 31 - 35, 01.06.2018

Sema Nur Ayyıldız Ömer Gökhan Doluoğlu

Abstract

Aim: In this study we aimed to determine
the status of the neutrophil lymphocyte
ratios of the new ISUP Gleason groups.

Material and Methods: Patients who
underwent transrectal ultrasound-guided
prostate biopsy and who had pathologically
proven prostate cancer were evaluated retrospectively.
Neutrophil / lymphocyte ratios of
all patients were determined. Their age, PSA
values and body mass index (BMI) were recorded.
Patients were assigned to 5 Gleason
groups according to ISUP 2014 definition. N
/ L ratios and other demographic data of the
groups were compared with each other.

Results: Data from 86 patients meeting
the study criteria were recorded. N/L ratios
were found as 2.13 (0.27-9.28) in group 1,
2.22 (0.27-1.52) in group 2, 2.40 (1.41-6.30)
in group 3, 1.90 (0.91-2.99) in group 4 and
2.11 (0.27-3.62) in group 5 (p=0.74).

Conclusion: N / L ratio was found to be
similar in all Gleason groups according to
present study. Prospective studies with large
patient populations are needed to determine
whether N / L ratio is a prognostic factor in
localized PCa patients or not.

Keywords

Gleason score , neutrophil to lymphocyte ratio , prostate cancer

Prostat biyopsisi yapılan hastalarda Gleason gruplarının tahmininde nötrofil/ lenfosit oranının önemi

Abstract

Amaç: Biz bu çalışmada lokalize prostat
kanserlerinde Gleason gruplarına göre, N/L
oranları arasında önemli bir fark olup olmadığını
araştırmayı amaçladık.

Gereç ve Yöntemler: Transrektal ultrason
eşliğinde prostat biyopsisi yapılan ve
patoloji sonucu prostat kanseri gelen hastalar
retrospektif olarak incelendi. Tüm hastaların
nötrofil/lenfosit oranları belirlendi. Yaşları,
PSA değerleri ve vücut kitle indeksleri (BMI)
kaydedildi. Hastalar ISUP 2014 tanımlamasına göre 5 gleason grubuna ayrıldı. Grupların
N/L oranları ve diğer demografik verileri birbirleri
ile karşılaştırıldı.

Bulgular: Çalışma kriterlerine uyan 86
hastanın verileri kaydedildi. Grupların N/L
oranları birbirleri ile karşılaştırıldığında
Grup 1’de 2.13 (0.27-9.28), grup 2’de 2.22
(0.27-1.52), grup 3’de 2.40 (1.41-6.30), grup
4’de 1.90 (0.91-2.99) ve grup 5’de 2.11 (0.27-
3.62) olarak saptandı (p=0.74).

Sonuç: Çalışmamıza göre N/L oranının
tüm Gleason gruplarında benzer olduğu saptanmıştır.
N/L oranının lokalize PCa hastalarında
prognostik bir faktör olup olmadığını
saptamak için geniş hasta serili prospektif
çalışmalara ihtiyaç vardır.

Keywords

Gleason skor , Nötrofil lenfosit oranı , Prostat kanseri

References

• 1. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136: E359-86.
• 2. Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM. Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care 2013; 51: 295-300.
• 3. Stamey TA, Yang N, Hay AR, Mc Neal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker foradenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-916.
• 4. Carter HB, Pearson JD, Metter EJ et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215-20.
• 5. Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279:1542-7.
• 6. Stephan C, Lein M, Junk K et al. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 1997;79:104-9.
• 7. Bryant RJ, Sjoberg DD, Vickers AJ et al. Predicting highgrade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. J Natl Cancer Inst 2015;107. pii: djv095.
• 8. Loeb S, Catalona WJ. The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol 2014;6:74-7.
• 9. Hessels D, Klein Gunnewiek JMT, van Oort I et al.DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44:8-16.
• 10. Partin AW, Mongold LA, Lamm DM et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001;58:843-8.
• 11. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM,Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71.
• 12. Templeton AJ, McNamara MG, Seruga B et al. Prognostic role of neutrophil to lymphocyte ratio in solid tumours:A systematic review and meta-analysis. J Natl Cancer Inst 2014;106:dju124. doi: 10.1093/jnci/dju124.
• 13. Ozcan C, Telli O, Ozturk E et al. The prognostic significance of preoperative leukocytosis and neutrophil-to-lymphocyte ratio in patients who underwent radical cystectomy for bladder cancer. Can Urol Assoc J 2015;9 (11-12):E789-94.
• 14. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. GradingCommittee. The 2014 International Society of Urological Pathology (ISUP)Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016;40:244-52. doi: 10.1097/PAS.0000000000000530.
• 15. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013 Jan 31;CD004720.doi:10.1002/14651858.CD004720.pub3.
• 16. Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specifi cantigen test: a review of current evidence. JAMA 2014 Mar 19;311:1143-9.doi: 10.1001/jama.2014.2085. Review. PubMed PMID: 24643604.
• 17. D’Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
• 18. Hu K, Lou L, Ye J, Zhang S. Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis. Br Med J Open 2015;5:e006404.
• 19. Ceylan C, Camtosun A, Doluoglu OG et al. Emphasis of neutrophil-to-lymphocyte ratio in non-metastatic renal cell carcinoma. Urologia. 2014 Jan-Mar;81:51-6. doi: 10.5301/ urologia.5000032.
• 20. Templeton AJ, Pezaro C, Omlin A et al. Simple prognostic score for metastatic castration –resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer 2014;120:3346-52.
• 21. Boegemann M, Schlack K, Thomes S et al. The role of neutrophil to lymphocyte ratio for survival outcomes in patients with metastatic castration-resistant prostate cancer treated with abiraterone. Int J Mol Sci 2017;18.
• 22. Pei XQ, He DL, Tian G et al. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer:roles of neutrophil-lymphocyte ratio in patients from Northwestern China. Int Urol Nephrol 2017;49:629-35.
• 23. Minardi D, Scartozzi M, Montesi L et al. Neuyrophil-tolymphocyte ratio may be associated with the outcome in patient with prostate cancer. Springerplus 2015;4:255.
• 24. Linton A, Pond G, Clarke S, Vardy J, Galsky M, Sonpavde G. Glaskow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clin Genitourin Cancer 2013;11:423-30.
• 25. Uemura K, Kawahara T, Yamashita D et al. Neutrophil-toLymphocyte ratio predicts prognosis in castration-resistant prostate cancer patients who received cabazitaxel chemotherapy. Biomed Res Int 2017;2017:7538647.
• 26. Naito H, Sugimoto M, Taketa S, Kakehi Y. Clinical significance of neutrophil-to-lymphocyte ratio in patients with prostate cancer. Hinyokika Kiyo 2017;63:63-67.
• 27. Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy Ann N Y Acad Sci 2013;1284:1-5.
• 28. Nind AP, Nairn RC, Rolland JM. Lymphocyte anergy in patients with carcinoma. Br J Cancer 1973;28:108-117.
• 29. Xiang YZ, Xiong H, Cui ZL et al.The association between metabolic syndrome and the risk of prostate cancer, highgrade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence. J Exp Clin Cancer Res 2013;32:9.
• 30. Bebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA. Features of the metabolic syndrome and prostate cancer in African-American men. Cancer 2007;109:875-81.
• 31. Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 2006;164:1094-1102.
• 32. Gokce MI, Tangal S, Hamidi N, Suer E, Ibis MA, Beduk Y. Role of neutrophil-to-lymphocyte ratio in prediction of Gleason score upgrading and disease upstaging in low-risk prostate cancer patients eligible for active surveillance. Can Urol Assoc J 2016;10:383-387.
• 33. Ceylan Y, Günlüsoy B, Degirmenci T et al. Neutrophil-tolymphocyte and neutrophil-to-monocyte rates in the decision for a prostate re-biopsy in patients with a previous benign pathology and consistently 2.5-10 ng/ml PSA value. Arch Esp Urol 2016;69:627-635.